mtor-in-8 — TargetMol Chemicals

Search Result

Search Results for " mtor-in-8 "

Compounds

Cat No.	Product Name	Synonyms	Targets
T36316	mTOR inhibitor-8	mTOR-IN-8	mTOR , Autophagy
	mTOR inhibitor-8 is a potent mTOR inhibitor and autophagy inducer with antiviral and antitumor activity. mTOR inhibitor-8 inhibits the growth of A549 cells, which can be used to study non-small cell lung cancer.		mTOR , Autophagy
T1958	AZ20		ATM/ATR , mTOR
	AZ20 is an effective and specific inhibitor of ATR kinase (IC50: 5 nM, in a cell-free assay), 8-fold selectivity over mTOR.		ATM/ATR , mTOR
T19661	8-Chloroadenosine	NSC 354258,8-Cl-Ado,NSC354258,NSC-354258	AMPK
	8-Chloroadenosine (NSC-354258) is a 5' AMP-activated protein kinase agonist potentially for the treatment of chronic lymphocytic leukemia. 8-chloroadenosine activity is associated with inhibition of the mTOR pathway.8-Ch...		AMPK
T63470	PI3K/mTOR Inhibitor-8
	PI3K/mTOR Inhibitor-8 is a dual inhibitor of PI3K (PI3Kα IC50: 0.46 nM) and mTOR (mTOR IC50: 12 nM). PI3K/mTOR Inhibitor-8 blocks the cell cycle of HCT-116 cells in G1/S phase and induces apoptosis. apoptosis).
T62580	PI3K-IN-37
	PI3K-IN-37 (Example 84.1) is an inhibitor of PI3K α (IC50: 6 nM), PI3K β (IC50: 8 nM) and PI3K δ (IC50: 4 nM). PI3K-IN-37 inhibits mTOR with an IC50 value of 4 nM.
T40483	8-Aminoadenosine	8-NH2-Ado
	8-Aminoadenosine (8-NH2-Ado) is an RNA-directed nucleoside analogue that effectively diminishes cellular ATP levels and impedes mRNA synthesis. Furthermore, it effectively obstructs Akt/mTOR signaling, inducing autophagy...
T36085	PKI-179 hydrochloride
	PKI-179 is an orally bioavailable dual inhibitor of PI3K and mammalian target of rapamycin (mTOR). In an in vitro enzymatic assay, it potently inhibits PI3K (IC50s = 8, 24, 17, and 74 nM for isoforms α, β, δ, and γ, resp...
T36084	PKI-179
	PKI-179 is a potent, orally active compound that functions as a dual PI3K/mTOR inhibitor. It demonstrates IC50 values of 8 nM for PI3K-α, 24 nM for PI3K-β, 74 nM for PI3K-γ, 77 nM for PI3K-δ, and 0.42 nM for mTOR. Additi...